Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to save Children's eyesight and lives from eye cancer in africa

NCT ID NCT04425434

Disease control Sponsor: French Africa Pediatric Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to improve survival and care for children with retinoblastoma, a rare eye cancer, in low-income African countries. Researchers will test whether following a set of treatment guidelines helps catch the disease early and leads to better outcomes. The study will enroll up to 3,000 children and track how many are diagnosed, what treatments they receive, and how many survive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

all children presenting at participating units who can be treated

Ages

Up to 18 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Unilateral intraocular Retinoblastoma (RB) * Unilateral extraocular intraorbital (RB) * Bilateral intraocular (RB) * bilateral intraocular (RB) on one side and extraocular but intraorbital on the other side. Exclusion Criteria: * Externalized tumor mass * massive extension to optic nerve up to optical channeltumor * intracranial extension leptomeninges * cerebral parenchyma * extension to regional lymph nodes and/or remote metastases. * cerebrospinal fluid involvement. * Trilateral RB * Incapacity to followed the whole treatement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Retinoblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

retinoblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Retinoblastoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Gabriel Touré (HGT)

    RECRUITING

    Bamako, Mali

  • CHU de Treichville à ABIDJAN

    RECRUITING

    Abidjan, Côte d’Ivoire

  • CUK (Cliniques Universitaires de Kinshasa)

    RECRUITING

    Kinshasa, Kinshasa City, BP 12 KIN XI, Democratic Republic of the Congo

  • Cliniques Universitaires de Lubumbashi (CUL)

    RECRUITING

    Lubumbashi, BP 1825, Democratic Republic of the Congo

  • HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona

    RECRUITING

    Antananarivo, Ampefiloha, BP 4150, Madagascar

  • Hopital Yalgado Ouedraogo

    RECRUITING

    Ouagadougou, 03 BP 7022, Burkina Faso

  • Hôpital Aristide Le Dantec,

    RECRUITING

    Dakar, BP 3001, Senegal

More trials for these conditions

Other studies related to the condition(s) this trial covers.